CoChat

Protein degradation technology: a strategic paradigm shift in drug discovery

Open access
Li, Haobin, Dong, Jinyun, Cai, Maohua, Xu, Zhiyuan, Cheng, Xiang-Dong, Qin, Jiang-Jiang · 2021 · Journal of Hematology & Oncology
Cited by 88

The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.

Abstract

Targeting pathogenic proteins with small-molecule inhibitors (SMIs) has become a widely used strategy for treating malignant tumors. However, most intracellular proteins have been proven to be undruggable due to a lack of active sites, leading to a significant challenge in the design and development of SMIs. In recent years, the proteolysis-targeting chimeric technology and related emerging degradation technologies have provided additional approaches for targeting these undruggable proteins. These degradation technologies show a tendency of superiority over SMIs, including the rapid and continuous target consumption as well as the stronger pharmacological effects, being a hot topic in current research. This review mainly focuses on summarizing the development of protein degradation technologies in recent years. Their advantages, potential applications, and limitations are also discussed. We hope this review would shed light on the design, discovery, and clinical application of drugs associated with these degradation technologies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13045-021-01146-7

Cites

54 of 54 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 54 references

Cited by

See all 88

Metadata

Authors
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X.-D., & Qin, J.-J.
Venue
Journal of Hematology & Oncology
Published
2021-09-06
Volume
14
Issue
1
Pages
138-138
ISSN
1756-8722 (ISSN-L)
OpenAlex
W3197741522
Cited by
88
References
54
FWCI
3.76
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protein degradation technology: a strategic paradigm shift in drug discovery. https://app.cochat.ai/papers/10.1186/s13045-021-01146-7
The paper
Li, H., Dong, J., Cai, M., Xu, Z., Cheng, X.-D., & Qin, J.-J. (2021). Protein degradation technology: a strategic paradigm shift in drug discovery. Journal of Hematology & Oncology. https://doi.org/10.1186/s13045-021-01146-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.